1. Home
  2. AEE vs NTRA Comparison

AEE vs NTRA Comparison

Compare AEE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEE

Ameren Corporation

HOLD

Current Price

$99.60

Market Cap

27.5B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$238.38

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEE
NTRA
Founded
1901
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.5B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
AEE
NTRA
Price
$99.60
$238.38
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$110.00
$246.44
AVG Volume (30 Days)
1.9M
1.1M
Earning Date
02-12-2026
02-26-2026
Dividend Yield
2.87%
N/A
EPS Growth
22.35
N/A
EPS
5.21
N/A
Revenue
$8,635,000,000.00
$2,116,676,000.00
Revenue This Year
$14.91
$33.18
Revenue Next Year
$5.92
$16.81
P/E Ratio
$19.02
N/A
Revenue Growth
23.25
38.17
52 Week Low
$87.04
$125.38
52 Week High
$106.73
$256.36

Technical Indicators

Market Signals
Indicator
AEE
NTRA
Relative Strength Index (RSI) 45.65 54.42
Support Level $98.80 $225.83
Resistance Level $101.28 $256.36
Average True Range (ATR) 1.41 6.93
MACD 0.17 0.53
Stochastic Oscillator 42.08 41.67

Price Performance

Historical Comparison
AEE
NTRA

About AEE Ameren Corporation

Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 800,000 natural gas customers across its two service territories.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: